Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.01SPGP 1.715ZUQ.TO 1.27NVDA 7.15GL 2.43MRK -3.06IEMG 1.96GEV 34.91
Patheon (PTI.TO)
The ultimate 360° Tracker Your financial life in one place, automatically

Patheon (PTI.TO)

0.00
-0.00 (0.00%)
6 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Patheon(PTI.TO)

Sep 27, 2004
Has disappointed for one too many quarters.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$9.15

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Patheon(PTI.TO)

Sep 21, 2004
In good industry. Havent been profitable in a few facilities, dealing with those issues. The stock is well priced. Could get a significant move with Patheon. Not much downside, compared to up.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$8.96

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Patheon(PTI.TO)

Sep 20, 2004
(A Top Pick May 31/04. Down 32%.) Had said that if it dropped through the base pattern, get out. It did.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$8.70

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Sep 17, 2004
Earnings forcasts have been falling right out of bed. Have not stabilized. Fair Market Value has been plunging.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$9.04

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Patheon(PTI.TO)

Sep 14, 2004
(A Top Pick Apr 28/04. Down 25%.) A torpedoed stock. Shows the need for having a basket. Will keep this stock.
Photo of Bill CarriganBill Carrigan
Owned
Unlock Rating
$8.62

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Sep 14, 2004
Likes the health care sector. Thinks it at the bottom of its trading range and expects an advance back to the low teens.
Photo of Bill CarriganBill Carrigan
Owned
Unlock Rating
$8.62

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Sep 08, 2004
Has delivered another poor quarter making it 3 or 4 in a row.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$8.25

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

Patheon(PTI.TO)

Aug 30, 2004
Wait and see if stock will go back up.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$8.83

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Aug 17, 2004
Still like the stock and holding it even though it has dropped. Extremely well-managed. One of the few profitable companies in the biotechnology sector.
Photo of Michael SprungMichael Sprung
Owned
Unlock Rating
$8.65

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Aug 16, 2004
Book value is around $4. FMV is around $13 but earnings forecasts have been really falling.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$8.75

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Aug 04, 2004
In theory, their business should work very well. Their English plant has been losing money. Their OTC line in Canada has been under some pressure.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$9.19

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jul 30, 2004
Model price at the beginning of the year was around $17 but is now $13.06 because earnings have been dropping. Stock could reach $11.30 but won't go above that.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$9.78

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Jun 21, 2004
Has been a top pick in the past and they continue to like it. Extremely well-run company. Expects them to bring on new products.
Photo of Michael SprungMichael Sprung
Owned
Unlock Rating
$10.72

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jun 18, 2004
Seem to have trouble getting their act together time after time. Last quarter, sales were lower than expected and costs were higher.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$10.88

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Jun 17, 2004
The market did not like their last quarter. Was probably oversold. Very capable management. Making a lot of money in the drug testing market. Good price.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$10.82

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 61 to 75 of 194 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.47$36.78
ET -0.025$19.045
MAIR 0$
RKLB 6.095$108.485
SESG-O 0$

Today's Top Picks

HMP.TO 0.01$9.76
SPGP 1.715$122.105
ZUQ.TO 1.27$108.74
NVDA 7.15$212.34
GL 2.43$169.19

Popular Articles

Latest Sell Signals

PRGO -0.14$10.85
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica